CHFR and neoplasm: The promoter methylation of CHFR has been described in several tumor types, such as gastric and colorectal adenocarcinoma (20–23), and has been also described as a potential biomarker for taxanes (24), irinotecan (25), or poly (ADP-ribose) polymerase (PARP) inhibitors (26) sensitivity.